Astrazeneca AB has 6 drugs losing patent protection between 2026 and 2031 in this data. The nearest is Bydureon (exenatide synthetic) on September 21, 2028; the company listed 72 patents on it with the FDA, and that is the last one to expire.
This is the earliest date a generic could enter; it is not a guarantee one will. We calculate it as the later of the last patent the company listed with the FDA and the last regulatory exclusivity. Companies often reach settlement agreements with generic makers for a different date, and those agreements are not public in this data.
Bydureon (exenatide synthetic)Astrazeneca AB · 72 patents · September 21, 2028
Onglyza (saxagliptin hydrochloride)Astrazeneca AB · 2 patents · November 30, 2028
Qtern (dapagliflozin; saxagliptin hydrochloride)Astrazeneca AB · 28 patents · June 16, 2030
Bydureon Bcise (exenatide synthetic)Astrazeneca AB · 47 patents · April 4, 2031
Xigduo XR (dapagliflozin; metformin hydrochloride)Astrazeneca AB · 50 patents · May 12, 2031
Qternmet XR (dapagliflozin; metformin hydrochloride; )Astrazeneca AB · 40 patents · May 12, 2031
Questions
How many Astrazeneca AB drugs lose patent protection between 2026 and 2031?
6 Astrazeneca AB drugs lose patent protection between 2026 and 2031 in this data.
What is Astrazeneca AB's nearest patent expiration?
Bydureon (exenatide synthetic) on September 21, 2028; the company listed 72 patents on it with the FDA.
Dates from the FDA Orange Book, the official record of which patents cover
which approved drug; updated monthly. Facts only, not investment advice. Verify against the
Orange Book and primary filings. pdufa.bio is not affiliated with the FDA.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.
Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.